Comprehensive benchmarking across in-domain and cross-domain DTI prediction tasks demonstrates that GPS-DTI outperforms existing methods, underscoring its strong generalization capability. Notably, the model achieves state-of-the-art performance on drug-target affinity (DTA) tasks and shows robust adaptability when evaluated on an independent Coronavirus Disease 2019 (COVID-19)-related test set. Furthermore, visualization of cross-attention maps offers interpretable insights into key molecular interactions, highlighting the potential of GPS-DTI in real-world drug discovery applications.
Xiong et al. (Wed,) studied this question.